ImmuPharma plc (LON:IMM – Get Rating) shares passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 5.94 ($0.07) and traded as low as GBX 4.50 ($0.05). ImmuPharma shares last traded at GBX 4.82 ($0.06), with a volume of 204,449 shares changing hands.
ImmuPharma Price Performance
The company has a 50 day simple moving average of GBX 5.88 and a 200-day simple moving average of GBX 5.94. The stock has a market cap of £15.83 million and a price-to-earnings ratio of -1.46. The company has a current ratio of 2.11, a quick ratio of 1.76 and a debt-to-equity ratio of 0.02.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.